Company Profile (AI Text)
Name: BioClonetics Immunotherapeutics
Canonical URL: https://wefunder.com/bioclonetics
Updated at: 2026-06-02T05:00:08Z

Tagline: Designing the first cure for HIV through the use of monoclonal antibodies
Elevator pitch: BioClonetics is finalizing the production and testing of a monoclonal antibody to treat patients with HIV. HIV is a virus that infects 37 million and kills approximately 1.2 million every year, and today there is still no cure. At BioClonetics, we've created a cell line that produces fully human monoclonal antibodies to specifically target and neutralize infectious diseases including HIV. If successful, this could be the first true cure for HIV at a fraction of the price of current treatment.

Key claims:
- Total raised on Wefunder: 386766 | citation: https://wefunder.com/bioclonetics#claim-total-raised
- Total investors: 586 | citation: https://wefunder.com/bioclonetics#claim-total-investors

Verified facts:
- Total raised on Wefunder: 386766 | observed_at: 2026-06-02T05:00:08Z | expires_at: 2026-06-03T05:00:08Z
- Total investors: 586 | observed_at: 2026-06-02T05:00:08Z | expires_at: 2026-06-03T05:00:08Z

Computed metrics:
- total_amount_raised: 386766
- total_investors: 586
- team_size: 7
- featured_investor_count: 0
- faq_count: 5
- recent_post_count: 1

Quick facts:
- We have created a cell line that produces an anti-HIV antibody called Clone 3. | citation: https://wefunder.com/bioclonetics#claim-fact-1
- We have demonstrated that Clone 3 neutralizes all clades and groups of HIV isolates. | citation: https://wefunder.com/bioclonetics#claim-fact-2
- We have identified that Clone 3 targets HIV at an immutable site on the HIV virus. | citation: https://wefunder.com/bioclonetics#claim-fact-3
- We expect to complete animal trials within 18 to 24 months. | citation: https://wefunder.com/bioclonetics#claim-fact-4
- We are working with several world-class laboratories who will assist us in conducting the next steps of our plan. | citation: https://wefunder.com/bioclonetics#claim-fact-5
- 1.2 million estimated people die from HIV each year. | citation: https://wefunder.com/bioclonetics#claim-fact-6
- 2 million estimated people are infected with HIV each year. | citation: https://wefunder.com/bioclonetics#claim-fact-7

FAQ:
- Q: On your website there is an investor page with a link to a Fundable campaign which no longer exists. Were you unsuccessful at raising money on Fundable?
  A: So that investors who are non-accredited may invest with accredited investors, we have chosen to seek funding using WeFunder.com rather than through Fundable. On WeFunder.com an investor may invest as little as $100.
- Q: Is your founder Joseph Paul Cotropia, NPI number 1912163924?
  A: One of the co-founders of our company is Joseph Paul Cotropia.
- Q: Do you require only accredited investors invest in your company?
  A: Investors are not required to be accredited investors to invest in our campaign.
- Q: It seams that Clone 3 was patented back in 1989. Can someone please provide a little back story on this cure? Why isn't this cure available to the public yet?
  A: Our company has indeed been the recipient of several early patents both in the US and in Europe covering the initial antibody discovery. This in itself speaks to the novelty of our technology. Those patents covered the non-commercial Clone 3 antibody produced by the parent cell line created by the company. As is usual, the parent cell line is a slow producer and a recombinant antibody must be produced in a fast producing CHO cell line and then tested to confirm efficacy leading to expected pa...
- Q: Hello. Is this Tier 1 or Tier 2 Reg A+ Crowdfunding?
  A: Our raise is neither but rather is a raise under Reg CF (crowdfunding).

Recent posts:
- BioClonetics Antibody Effectively Neutralizes 95% of HIV Isolates (2018-07-05T17:45:13Z) https://wefunder.com/feed/92108